These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19908299)

  • 41. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
    J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The success of primary chemotherapy for group D heritable retinoblastoma.
    Cohen VM; Kingston J; Hungerford JL
    Br J Ophthalmol; 2009 Jul; 93(7):887-90. PubMed ID: 18703556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
    Schefler AC; Cicciarelli N; Feuer W; Toledano S; Murray TG
    Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trilateral retinoblastoma: a systematic review and meta-analysis.
    de Jong MC; Kors WA; de Graaf P; Castelijns JA; Kivelä T; Moll AC
    Lancet Oncol; 2014 Sep; 15(10):1157-67. PubMed ID: 25126964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.
    Geyer JR; Sposto R; Jennings M; Boyett JM; Axtell RA; Breiger D; Broxson E; Donahue B; Finlay JL; Goldwein JW; Heier LA; Johnson D; Mazewski C; Miller DC; Packer R; Puccetti D; Radcliffe J; Tao ML; Shiminski-Maher T;
    J Clin Oncol; 2005 Oct; 23(30):7621-31. PubMed ID: 16234523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
    Choi LM; Rood B; Kamani N; La Fond D; Packer RJ; Santi MR; Macdonald TJ
    Pediatr Blood Cancer; 2008 May; 50(5):970-5. PubMed ID: 17941070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma.
    Torbidoni AV; Sampor C; Laurent VE; Aschero R; Iyer S; Rossi J; Alderete D; Alonso DF; Szijan I; Chantada GL
    Br J Ophthalmol; 2018 Nov; 102(11):1597-1601. PubMed ID: 30150278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma).
    Shields CL; Meadows AT; Shields JA; Carvalho C; Smith AF
    Arch Ophthalmol; 2001 Sep; 119(9):1269-72. PubMed ID: 11545631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma.
    Turaka K; Shields CL; Meadows AT; Leahey A
    Pediatr Blood Cancer; 2012 Jul; 59(1):121-5. PubMed ID: 21826785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America.
    Palma J; Sasso DF; Dufort G; Koop K; Sampor C; Diez B; Richard L; Castillo L; Chantada GL
    Bone Marrow Transplant; 2012 Apr; 47(4):522-7. PubMed ID: 21602901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of a prospective study for the treatment of unilateral retinoblastoma.
    Chantada GL; Fandiño AC; Guitter MR; Raslawski EC; Dominguez JL; Manzitti J; de Dávila MT; Zubizarreta P; Scopinaro M
    Pediatr Blood Cancer; 2010 Jul; 55(1):60-6. PubMed ID: 20486172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
    Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
    Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide.
    Varan A; Kiratli H; Aydın B; Tarlan B; Poyraz CB; Akyüz C; Büyükpamukçu M
    Pediatr Hematol Oncol; 2012 Sep; 29(6):529-37. PubMed ID: 22759219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.
    Bartuma K; Pal N; Kosek S; Holm S; All-Ericsson C
    Acta Ophthalmol; 2014 Aug; 92(5):404-11. PubMed ID: 24119165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement.
    Antoneli CB; Ribeiro KB; Rodriguez-Galindo C; Soares FA; Arias VA; Novaes PE; Chojniak MM; Malogolowkin M
    J Pediatr Hematol Oncol; 2007 Oct; 29(10):700-4. PubMed ID: 17921851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma.
    Wilson MW; Haik BG; Liu T; Merchant TE; Rodriguez-Galindo C
    Am J Ophthalmol; 2005 Sep; 140(3):397-406. PubMed ID: 16138999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful treatment of neonatal trilateral retinoblastoma.
    Bindlish R; LaRoche GR
    J AAPOS; 1999 Dec; 3(6):376-8. PubMed ID: 10613584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.